All News
Pegloticase in Severe Refractory Gout
Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting.
Read Article
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup
Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.
Read Article
#BestACRO20Tweets
"RT @RHEUMarampa : Large cohort of older RA pts newly rx w/HCQ or MTX:
👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ.
@RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/4gK7hwdhIr" https://t.co/JsGBFrp7Hl
Links:
Dr. John Cush RheumNow ( View Tweet)
Did you know we have podcast? Search Rheum Now on Apple/Android/Soundcloud or listen directly through the link below.
https://t.co/wjBWCrKL34 https://t.co/Sin6gVXbeB
Links:
Dr. John Cush RheumNow ( View Tweet)
Miss anything during #ACR20? The RheumNow podcast has got it covered.
Catch our podcast on ACR20-Opening Day.
https://t.co/dG2H80Qycw https://t.co/EzNl4lm1fB
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/knduk3l6xV https://t.co/SNommxn1jA
Links:
Dr. John Cush RheumNow ( View Tweet)
SKIPPAIN Trial: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0899 presented at #ACR20.
https://t.co/yoQ8MEH2Br https://t.co/1uRKEp88le
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Worth checking out the #ACR20 image competition. Here's an image of cerebral toxoplasmosis during ADA treatment for RA https://t.co/JH07pMjvRe https://t.co/H9LHwiw4xL
Links:
Dr. John Cush RheumNow ( View Tweet)
Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952 presented at #ACR20.
https://t.co/xeiMYLZEQa https://t.co/a4RJ6BrNgn
Links:
Dr. John Cush RheumNow ( View Tweet)
Vaccination with Shingrix: Does it work for patients on JAKi? #ACR20
https://t.co/PLWn3SshcI https://t.co/APBcfP1zlH
Links:
Dr. John Cush RheumNow ( View Tweet)
Nomenclature, Uveitis and Other Spondyloarthritis Features with Dr. Lianne Gensler #ACR20
https://t.co/zql7iySXOA https://t.co/PY9k108QTc
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts.
Double-blind, Placebo, RCT (n=243)
@RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/Gi5FpodeKf https://t.co/bTk8n7dNni
Links:
Dr. John Cush RheumNow ( View Tweet)
Warfarin and Risk of Hip and Knee Replacements with Dr. Mrinalini Dey ( @DrMiniDey) #ACR20. https://t.co/znTxIx1QQZ https://t.co/elQlChwr0N
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Let us know your thoughts on our article titled "Undifferentiated Autoinflammatory Syndrome Called VEXAS"
https://t.co/afNK3UuZef #ACR20 https://t.co/fp2sX9w894
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @synovialjoints : Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894
Dr. John Cush RheumNow ( View Tweet)
Dr. Kathryn Dao ( @KDAO2011) reviews abstract #0533 presented at #ACR20 on male osteoporosis.
https://t.co/Z0NLcJzslV https://t.co/SSoIA7Eetg
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrMiniDey : Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment.
Abs#2000 #ACR20
https://t.co/lMYlXgaHyE https://t.co/0Fdone9yb3
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab
Links:
Dr. John Cush RheumNow ( View Tweet)
Did you know we have podcast? Search Rheum Now on Apple/Android or listen directly through the link below.
https://t.co/wjBWCrKL34 https://t.co/yhZ2wyujA0
Links:
Dr. John Cush RheumNow ( View Tweet)